Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

13,920.00
1 Aug 2013
Price Change (% chg)

-200.00₪ (-1.42%)
Prev Close
14,120.00₪
Open
14,100.00₪
Day's High
14,100.00₪
Day's Low
13,800.00₪
Volume
680,176
Avg. Vol
444,245
52-wk High
16,580.00₪
52-wk Low
13,510.00₪

TEVA.TA

Chart for TEVA.TA

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.32
Market Cap (Mil.): ₪132,843.70
Shares Outstanding (Mil.): 944.15
Dividend: 115.00
Yield (%): 3.05

Financials

  TEVA.TA Industry Sector
P/E (TTM): 19.75 37.93 37.76
EPS (TTM): 7.12 -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

Teva Pharm faces U.S. patent worries, dip in profits

JERUSALEM - Teva Pharmaceutical Industries profits fell in the second quarter, hurt by a decline in U.S. and European generic drug sales, and its near-term outlook looks bleak in the face of prospective competition for multiple sclerosis drug Copaxone.

1:16pm EDT

CORRECTED-UPDATE 1-Teva Pharm faces U.S. patent worries, dip in profits

(Corrects 12th paragraph to show CEO said expects stronger fourth quarter, not stronger 2014)

1:12pm EDT

U.S. court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.

26 Jul 2013

UPDATE 1-US court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK, July 26 - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.

26 Jul 2013

U.S. court permits generic version of Teva MS drug a year sooner

WASHINGTON, July 26 - Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court Friday.

26 Jul 2013

Lonza scraps generic drug venture with Teva

ZURICH/LONDON - Specialty chemicals maker Lonza posted a bigger than expected fall in first-half profit and said it was ending a generic drugs venture with Israel's Teva Pharmaceutical Industries by mutual agreement after misjudging how much it would cost.

25 Jul 2013

UPDATE 2-Lonza scraps generic drug venture with Teva

ZURICH/LONDON, July 25 - Specialty chemicals maker Lonza posted a bigger than expected fall in first-half profit and said it was ending a generic drugs venture with Israel's Teva Pharmaceutical Industries by mutual agreement after misjudging how much it would cost.

25 Jul 2013

Teva and Lonza to end collaboration on biosimilars

ZURICH, July 25 - Israel-based Teva Pharmaceutical Industries and Swiss Lonza Group said they were discontining their collaboration for the development, manufacturing and marketing of biosimilars.

25 Jul 2013

Teva developing new medicines to treat brain disorders -CEO

JERUSALEM, July 23 - Teva Pharmaceutical Industries expects to complete development of new medicines in the next few years aimed at treating brain disorders as the global population ages, its chief executive said.

23 Jul 2013

Mylan says court dismisses some of Teva's patent claims on MS drug

- A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.

16 Jul 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks